Physician Education (CME)<\/b><\/p>\n
Physician Education Key Opinion Leaders, Medical Science Liaisons, & CME![\"PhysEd](\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2019\/02\/PhysEdcover.jpg\")
It’s a new era for pharmaceutical company support of physician education. New guidelines and regulations from various governmental and non-governmental regulatory bodies have come into play during the past few years. The second event defining this new era was the withdrawal of Vioxx from the market in 2004 and the subsequent re-emergence of the importance of physicians as “learned intermediaries.” <\/p>\n
More than ever, it is important to educate physicians about new drugs and to keep this education separate from the marketing function of the company yet aligned with commercial goals. <\/p>\n
This Special Supplement to Pharma Marketing News<\/i> is critical reading for pharmaceutical companies and physician education service providers wishing to understand the new roles of key opinion leader physicians (KOLs) and medical science liaisons (MSLs) in the physician education process. <\/p>\n
approx. 27 pages<\/i>. <\/p>\n
Download this collection now. It’s FREE…<\/b> <\/p>\n
Access Full Article Here<\/a><\/b><\/p>\n<\/p>\n Reprint List Adobe Connect for eDetailing<\/strong> <\/p>\n Making Physician Communications More Effective<\/i><\/p>\n This article focuses on Adobe Connect for eDetailing, a specific collaboration between Adobe and ConnectSolutions, a leading provider of private cloud deployments of web conferencing and collaboration solutions.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Branded Physician Education: How to Integrate Promotion and Education<\/strong> <\/p>\n While funding for CME may have shifted out of the control of the marketing departments at most pharma companies, there is still a desire for marketing to reach out to physicians with educational promotional programs that are more within their control. MedPoint Communications, a marketing and educational services company headquartered in Evanston, IL, manages multi-channel, “within label medical education” programs for its pharmaceutical clients.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Building the “New” Pharma Physician Marketing Model<\/strong> <\/p>\n MedTera’s HC Professional “Life Long Learning” Platform<\/i><\/p>\n This article reviews MedTera’s HC Professional “Life Long Learning” Platform — branded integrated physician marketing solutions — and presents a summary of research on how brand teams see the mix of marketing tactics changing over the next several years. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Capturing & Reporting HCP-Related Meeting Spending<\/strong> <\/p>\n Let the Sunshine In<\/i><\/p>\n Life Science companies are struggling to understand the complex reporting requirements and compliance issues presented by existing and new regulations like the Sunshine Act. This article is a summary of a Webinar by StarCite, which defined what pharma marketers and meeting planners need to know when it comes to meetings-related HCP reporting.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Certain Physician-Drug Industry Relationships Have Declined Dramatically<\/strong> <\/p>\n Sunshine Act May Already Be Causing Sharp Drop in Direct Payments to Physicians<\/i><\/p>\n The authors of a physician survey published in the November 8, 2010, issue of Archives of Internal Medicine conclude ‘given that 83.8% of physicians have PIRs, it is clear that industry still has substantial financial links with the nation’s physicians. These findings support the ongoing need for a national system of disclosure of PIRs [Physician-Drug Industry Relationships].’ Such a system is part of the Physician Sunshine Law, which is scheduled to go into effect in 2012 with public disclosure of payments scheduled to begin September, 2013.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n The Changing Landscape of Physician Interactions<\/strong> <\/p>\n Pharmaceutical companies are under increasing pressure to reduce costs, speed the time-to-market for new products and ensure that physicians are informed and educated about their products. <\/p>\n MERGE Rx recognizes this need and offers a new generation of Web-enabled software that helps pharmaceutical companies manage physician interactions — including key opinion leader (KOL) management, phaseIV trials, and eDetailing — from a single, secure and scalable access point. <\/p>\n Topics and issues covered include: <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n The Changing World of MSLs: Determining Value<\/strong> <\/p>\n This article is an edited transcript of the May 2006, Pharma Marketing Roundtable discussion, which was devoted to exploring issues surrounding the new roles of medical science liaisons (MSLs) and key opinion leader physicians (KOLs) in physician education and product marketing.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Checking Under the Hood of Pharma Mobile Apps<\/strong> <\/p>\n Be Aware of What’s Behind the App: Disclaimers Tell Only Part of the Story<\/i><\/p>\n Let’s look ‘under the hoods’ of two pharma-sponsored mobile apps and compare disclaimers. We’ll compare Janssen’s PASI calculator, which has an update disclaimer, with the new AFib Educator 2.0 app developed by Sanofi-Aventis.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n CME Provider\/Pharmaceutical Partnerships – Are They Possible Without Conflict of Interest?<\/strong> <\/p>\n This article answers the following questions regarding pharma support of academic CME providers: What strategies should a pharmaceutical company follow to ensure a successful partnership with an academic CME provider? What’s an appropriate measure for outcomes (ROI)? What % of income from academic CME programs comes from pharma support? <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Collaborating with Online Physician Communities<\/strong> <\/p>\n Pharma-Physician Peer-to-Peer Dialog via Sermo<\/i><\/p>\n Pfizer and Sermo — a Web-based community where physicians share observations from daily practice, discuss emerging trends and provide new insights into medications, devices and treatments — recently announced a “strategic collaboration designed to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care.” <\/p>\n To answer the many questions raised by this collaboration — including concerns about off-label communications — Pharma Marketing News<\/i> invited Daniel Palestrant, M.D., founder and CEO of Sermo, to be a guest on a recent Pharma Marketing Talk podcast. <\/p>\n This article is based partly on that interview as well as other sources. <\/p>\n Topics and issues covered include: <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Compliance with (Some) New ACCME Rules Not So Easy<\/strong> <\/p>\n At the end of September 2004, the seven member organizations of the Accreditation Council for Continuing Medical Education (ACCME\u00ae) unanimously approved the 2004 Updated ACCME Standards for Commercial Support: Standards to Ensure the Independence of CME. When these rules go into effect in July 2005, it is unclear how they will affect industry participation and support of CME or how these rules change the status quo for Providers soliciting CME support from industry. A panel of experts at the recent CBI 5th Annual Continuing Medical Education conference in Princeton, NJ tackled these issues. The discussion is summarized in this article. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Crowd Sourced Creative Commons Drug Information<\/strong> <\/p>\n Pitfalls & Opportunities for Pharma<\/i> <\/p>\n Whether or not it is “beneficial” for pharma company employees to edit Wikipedia information about their own company’s products is difficult to know for certain. This article summarizes the pros and cons of pharmaceutical companies editing Wikipedia articles to correct “misinformation” about their drugs.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Direct to Physician Telemarketing and Sales<\/strong> <\/p>\n The point of diminishing returns in the sales trench warfare has been reached. For most companies it makes no sense economically to add field staff, especially to cover “white” territories spread across large, mostly rural areas. Another option is telemarketing offered by companies such as ADG Pharmaceutical Biotech Marketing (ADG), which specializes in providing hosted telemarketing services for the pharmaceutical, life sciences and biotech industries. <\/p>\n Topics covered include: <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n The Emerging Virtual Medical Conference<\/strong> <\/p>\n Opportunities for Pharma, HCPs and Patients<\/i><\/p>\n This article describes the changes occurring viz-a-viz major medical conferences and the impact this will have on the pharmaceutical industry, medical societies, healthcare professionals, and patients. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Facilitating Physician Access and Education Through Online Conferencing<\/strong> <\/p>\n Access to physicians is becoming more and more of a problem. Doctors need immense amounts of medical information, but their patient loads limit their ability to see pharma sales reps or attend conferences or other educational activities away from their offices at such venues as local restaurants and hotels. And it is impractical to bring KOLs and experts into the physician’s office. One way to bring these resources to physicians is through Web conferencing. This report describes a turnkey system that is being used effectively to host 6,000 live online events per year, attended by some 300,000 physicians around the world. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Fast Start to Customized ePromotion and eLearning Physician Programs<\/strong> <\/p>\n There is a broad spectrum of online promotional and educational opportunities that pharmaceutical companies have at their disposal to interact with, inform, and influence physicians. Lathian Systems, a provider of online marketing and sales solutions, offers these and more in its Spectrum of Solutions for life science companies.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n FDA Finalizes Guidance on Distribution of Reprints<\/strong> <\/p>\n Clarifies How Manufacturers Can Hand Out Journal Articles to Docs<\/i><\/p>\n The FDA recently finalized its Good Reprint Practices for the Distribution of Medical Journal Articles. This article outlines the major provisions of the guidance and helps you learn how to make it work for your company. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n FDA’s Good Reprint Practices Guidance<\/strong> <\/p>\n Pros and Cons of the Proposed Rules for Distribution of Off-Label Information<\/i> <\/p>\n Medical journals may soon become the pharmaceutical industry’s newest physician marketing partner. On Friday, February 15, 2008, the FDA published its draft guidance on “Good Reprint Practices for the Distribution of Medical Journal Articles … on Unapproved New Uses of Approved Drugs…” <\/p>\n This article summarizes some of issues raised by FDA’s proposal that pundits and experts are debating on the Internet, in the press and in official comments submitted to the FDA. It also presents preliminary results of an online survey<\/a> sponsored by Pharma Marketing News<\/i>. <\/p>\n Topics and issues covered include: <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Free Gifts to Physicians: What’s the Big Deal?<\/strong> <\/p>\n Pharma Marketing News hosted an online survey and a Pharma Marketing Expert Roundtable discussion on the topic of pharma gifts to physicians. This article summarizes the findings of that survey and includes comments and insights from survey respondents and Roundtable members.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Gamification<\/strong> <\/p>\n Now and Then<\/i> <\/p>\n There’s a lot of brouhaha these days in pharma circles about ‘gamification’ as if it were the newest thing since sliced bread. These days, however, it may be easier for a pharma company to create a real-life museum educational gaming experience than a virtual world game on Facebook. Way back in 1984, gamification was much simpler.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Hard Sell: The Evolution of a Generation X Salesman<\/strong> <\/p>\n This scathing review of the book ‘Hard Sell: The Evolution of a Viagra Salesman,’ which is a tell-a-lot-but-not-all about pharmaceutical sales, explores the connection between flagging sales force effectiveness and the generation gap between Boomers and Gen-Xers. ‘Dude,’ read it! <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n The Internet and CME<\/strong> <\/p>\n Despite the fact that physician usage of the Internet has increased over the past few years, solid evidence for the reasons they access the Internet or, more importantly, if the knowledge they gained from online CME presentations has any impact on their practice is still largely unknown.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n The iPad as a Pharma Marketing Platform<\/strong> <\/p>\n Is It a Game-Changer for Consumer & Physician Access?<\/i><\/p>\n This article summarizes how the iPad is currently being used by the pharmaceutical industry, how it is being adopted by physicians, and what the roadblocks are to using it for eDetailing.<\/p>\n Topics include:<\/p>\n Many Physicians Plan to Buy It<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n The iPad in the Doctor’s Office<\/strong> <\/p>\n Understanding What Physicians and Patients Desire from mHealth Applications<\/i><\/p>\n The Apple iPad has also become a “must have” for pharmaceutical sales reps, but how are physicians and their patients using the iPad within the clinical setting? That was the focus of a study done by a team consisting of healthcare professionals in an NYU Langone Medical Center department, led by Douglas Elwood, MD, MBA, who is currently Director, GMI Strategy and Innovation at Bristol-Myers Squibb. This article reviews the latest results of that study.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Is It Time to End Industry Sponsored CME?<\/strong> <\/p>\n Preliminary results from a survey of Pharma Marketing News<\/i> readers about their views regarding industry sponsorship of accredited CME, including views on value, bias, ACCME firewalls, and alternative means of CME support.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Limiting Bias in Commercially Supported CME<\/strong> <\/p>\n How Can Bias in Commercially-Sponsored CME Be Limited?<\/i><\/p>\n Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Managing Medical Science Liaisons From Afar<\/strong> <\/p>\n Managing a winning team of Medical Liaisons, MLs, from afar, not only demands proper selection of highly driven, self-motivated and scientifically-fluent professionals, but also requires a manager’s recognition and vision of ‘top-down-bottom-up’ leadership style: consistent, rapid long distance communication, a team-shared vision of goals and responsibilities, and a working foundation of trust for overall success and ML job satisfaction. This article reviews a presentation made by Mario Sylvestri, Pharm.D, PhD, Senior Director Medical Informatics and Communications, Amylin Pharmaceuticals. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Medical Science Liaisons: Working between Two Worlds<\/strong> <\/p>\n Medical Science Liaisons (MSLs) have assumed a pivotal role interfacing between pharmaceutical and biotechnology companies and the opinion and thought leaders (OTLs) who influence how medicine is routinely practiced. This article highlights how MSLs can maximize their unique position to help improve medical care while they enhance their companies’ bottom lines. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Mobile Medical Reference: An Effective Door Opener for Sales Reps<\/strong> <\/p>\n Pharmaceutical companies are searching for new, creative solutions to the problem of decreasing sales rep effectiveness. One such solution is to provide physicians with value-added smart tools to allow them instant access to up-to-date prescribing and treatment information. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Mobile Regulatory Fears<\/strong> <\/p>\n PhRMA Raises an Alarm<\/i><\/p>\n In a blog post provocatively titled ‘An App for That, But For How Much Longer?’, PhRMA’s Kate Connors agreed with a Washington Times op-ed piece that suggested the FDA will soon require apps such as medication prescription renewal reminders and blood glucose level tracking functions to be regulated as medical devices. The op-ed author, Joel White, executive director of the Health IT Now Coalition, suggests that this effort would lead to increased costs as well as constraints on user access to these apps, which ‘may cause developers to move on to other, less burdensome endeavors.’ ‘In the end, this could hinder the way that patients can actively improve their own care,’ said Conners. Is this fear warranted? Are there apps that SHOULD be regulated by the FDA? Read this article and find out.<\/p>\n Read the article<\/a><\/b> <\/p>\n<\/p>\n Motivating & Retaining The MSL: What Makes MSLs Tick<\/strong> <\/p>\n In addition to her clinical and professional role as an experienced and successful MSL for Sepracor in the Indianapolis, IN area, Erin Albert, R.Ph, MBA, has spent a considerable amount of time researching and gathering psychometric data about her peers’ job satisfaction in their current MSL roles. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n MSL Role in Educational Development<\/strong> <\/p>\n This article reviews a presentation by Bob Reina, MS, MBA, Vice President of the Veritas Institute for Medical Education, and Sharon Schneider, PsyD, MBA, Program Director, Medical Education, Ortho-McNeil Pharmaceuticals Inc., entitled “Field Liaisons Team Effectiveness, The Role of the MSL in the Medical Education Setting.”. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n MSL Roles & Goals<\/strong> <\/p>\n MSLs Need Variety of Talents<\/i><\/p>\n Medical Science Liaisons (MSLs) today face unprecedented challenges in developing and managing strong clinically-focused relationships with key opinion leaders (KOLs). Many presenters at a recent CBI Annual Forum on Field-Based Dissemination of Scientific Information held in Philadelphia spoke candidly and openly about these challenges and how they are being met by the industry. <\/p>\n This article summarizes several presentations made at this meeting. <\/p>\n Topics covered include: <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Multichannel Marketing<\/strong> <\/p>\n Easy to Brag About, but Difficult to Do<\/i> <\/p>\n Multichannel pharma marketing is conceptually relatively simple to understand, but incredibly difficult in practice, says Len Starnes, former Head of Digital Marketing & Sales, General Medicine at Bayer Schering Pharma. That said, multichannel is not a transient phenomenon, it’s here to stay. Starnes hosted a survey on LinkedIn to answer the question: When will pharma marketing become de facto multichannel marketing in future?<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Multichannel Marketing & Medical Reprints<\/strong> <\/p>\n Putting Science on iPads, Apps, and HCP Websites<\/i><\/p>\n The distribution of medical reprints to healthcare professionals (HCPs) by sales reps is not only a logistical problem but a channel problem as well. Reprints Desk helps pharmaceutical companies to deploy copyrighted e-prints and other marketing materials via iPads and other tablets, or via their own apps and websites in a controlled manner as part of a multichannel marketing campaign.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Murky Physician Marketing and Education Practices<\/strong> <\/p>\n This commentary takes a look at some “murky” (ie, non-transparent) physician marketing practices and presents opinions from several Pharma Marketing Blog polls and commentators. <\/p>\n Topics and issues covered include: <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Online CME – A Glass Half-Full or Half-Empty?<\/strong> <\/p>\n This article looks at data regarding online CME – number of physicians doing CME online, etc. It also includes a case study of a popular pharma-sponsored online CME program, which highlights the necessary ingredients for success. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Pharma Begins to Reveal Payments to Physicians<\/strong> <\/p>\n Analyzing the Numbers and Spreading the Sunshine<\/i><\/p>\n This article reviews the physician payment lists published by Lilly, Merck, and GSK. The analysis gives us more insight into the fees paid by various companies, how the money was distributed by state and region in the US, and what types of activities (eg, speaker fees vs. consulting fees) physicians were paid to perform. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Pharma, Physicians, and Sermo: A Social Media Win-Win-Win!<\/strong> <\/p>\n A Social Media Win-Win-Win!<\/i><\/p>\n This article provides an overview of Sermo’s new Client Center and summarizes a Pharma Marketing Talk podcast interview of with Daniel Palestrant, Sermo’s Founder and Chief Executive Officer. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Pharma-Sponsored Medical Ghostwriting: What the Ghosts Have to Say About It<\/strong> <\/p>\n What the Ghosts Have to Say About It<\/i><\/p>\n Pharma Marketing News<\/i> surveyed readers to determine if medical journal articles sponsored and ghostwritten by drug companies are a legitimate part of marketing to physicians and to get opinions on various other issues raised in the press about ghostwriting. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n PhRMA Code Helps Re-define Roles of Medical Affairs and Marketing<\/strong> <\/p>\n This article discusses marketing to physicians in light of the industry self-regulatory Code on Interactions with Healthcare Professionals as well as the final OIG Compliance Program Guidance for Pharmaceutical Manufacturers. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n PhRMA Code Succeeding — So Far<\/strong> <\/p>\n This article summarizes the views of Scott Willoughby, Senior Manager of Ernst & Young and former Assistant General Counsel to the Pharmaceutical Research and Manufacturers of American (PhRMA) with regard to the current state of compliance with the PhRMA Code on Interactions with Healthcare Professionals and how it is impacting sales effectiveness. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n PhRMA’s Code on Interactions with Healthcare Professionals<\/strong> <\/p>\n To better understand the impact on the pharmaceutical industry of PhRMA’s Code on Interactions with Healthcare Professionals, Pharma Marketing News<\/i> surveyed readers between July 10, 2008 and August 7, 2008, and collected comments from pharma-focused blogs and bulletin boards. This article is a summary of the PMN survey results and opinions of experts, bloggers, and anonymous commentators.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Physician-Generated Content on Social Media Sites<\/strong> <\/p>\n Survey of DocCheck Members<\/i><\/p>\n This article highlights results of a survey of physician members of DocCheck, a leading European physician online social network and portal site. The survey assessed the type of networks used, the frequency of posting, motivation for posting, estimation of network usage, relevance of content posted and an evaluation of the importance of online physician-generated content in the future. <\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Physicians Are Concerned About Pharma Support of CME<\/strong> <\/p>\n But Are Unwilling to Pay Their Own Way!<\/i><\/p>\n Talk about having your cake and eating it too! Commercial funding of continuing medical education (CME) and the potential for bias appear to concern many physicians, yet only a TINY MINORITY (7%) are willing to pay registration fees to eliminate or offset commercial funding sources, according to a report in the May 9, 2011, issue of Archives of Internal Medicine, one of the JAMA\/Archives<\/i> journals.<\/p>\n Access Full Article Here<\/a><\/b> <\/p>\n<\/p>\n Physician Meetings<\/strong> <\/p>\n Education Works Both Ways<\/i><\/p>\n This article reviews the physician meeting logistics and planning capabilities of Alliance Communications, which has worked with pharma companies and key opinion leaders since 1987. <\/p>\n\n
\n
\n
\n
\n
\n
\n